CAR-T Therapy – Medxy AI

The 2024 EBMT Activity Report: Crossing One Million HCTs and 20,000 CAR-T, a Landmark in Cellular Therapy

By MedXY 05/30/2026

EBMT’s 2024 report marks over one million reported stem cell transplants and continued rapid CAR-T growth, highlighting shifts in indications, donor use, and access across Europe.

$Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4$

Hematology-Oncology news

Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4

By MedXY 02/19/2026

The updated CARTITUDE-4 analysis demonstrates that cilta-cel significantly improves overall survival and progression-free survival compared to standard therapies in lenalidomide-refractory multiple myeloma patients after the first relapse, marking a potential shift in the treatment paradigm.

Clinical Updates Hematology-Oncology news

Clinical Evolution of Axicabtagene Ciloleucel: From Salvage Therapy to Second-Line Standard of Care

By MedXY 01/13/2026

This review synthesizes clinical trial evidence for Axicabtagene Ciloleucel, tracing its development from refractory B-cell lymphoma to its current role as a second-line standard and its expansion into indolent and mantle cell lymphomas.

$Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia$

Hematology-Oncology news Oncology

Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia

By MedXY 12/18/2025

Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patients with relapsed T-cell acute lymphoblastic leukemia.

$Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1$

Clinical Updates Hematology-Oncology news Specialties

Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1

By MedXY 09/09/2025

CARTITUDE-1 demonstrates that a single infusion of ciltacabtagene autoleucel (cilta-cel) yields durable ≥5-year remission and extended survival in heavily pretreated relapsed/refractory multiple myeloma, with compelling MRD negativity and a favorable safety profile.

$Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients$

Clinical Updates Hematology-Oncology Medical News Specialties

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

By MedXY 08/01/2025

A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.